<i>In vitro</i>and<i>in vivo</i>anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile
Shuhei Suzuki(Yamagata University), Masashi Okada(Yamagata University)
Cited by 23
Related Papers
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells
|Oncotarget|2014|94
Targeting the K-Ras - JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation
|Oncotarget|2014|74
The novel JNK inhibitor AS602801 inhibits cancer stem cells <i>in vitro</i> and <i>in vivo</i>
|Oncotarget|2016|59
Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
|Oncotarget|2018|56
JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression
|International Journal of Oncology|2013|54